You are here: Industry Insights > Abcam

News List

CR UK pairs with Abcam pharmatimes
July 09, 2020
Cancer Research UK (CR UK) has paired with Abcam to develop and commercialise novel custom antibodies to support the acceleration of cancer research.
Abcam Announces Successful Acquisition of Expedeon's Proteomics and Immunology Business, Enhancing Its Conjugation Capability prnasia
January 06, 2020
Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business, which includes Innova and TGR Biosciences, as of 1st January 2020.
Abcam and SomaServe Announce Comprehensive Partnership to Realise the Potential of PolyNaut® 'Bionic' Nanoparticles for Delivery to Live Cells b3cnewswire
December 18, 2019
Abcam plc, a global innovator in life science reagents and tools, and SomaServe Ltd, a Pharma service and specialist reagent business exploiting PolyNaut® Technology ...
Abcam and BrickBio Announce a Partnership to Incorporate Conjugation-Ready Sites into Recombinant Antibodies Across Abcam’s Portfolio b3cnewswire
November 12, 2019
Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company ...
Abcam and BrickBio Announce a Partnership to Incorporate Conjugation-Ready Sites into Recombinant Antibodies Across Abcam’s Portfolio b3cnewswire
November 12, 2019
Abcam plc, a global innovator in life science reagents and tools, is today pleased to announce a strategic partnership with BrickBio, experts in site-specific protein modification and a Tiger Gene portfolio company ...
Abcam acquires EdiGene’s Knock-out cell lines and Lysates Portfolio biospectrumasia
July 17, 2019
Using their proprietary high throughput cell editing platform, EdiGene developed the industry’s largest off-the shelf diploid library of over 2,800 single clonal knockout (KO) cell lines
Abcam Merck Collaboration Produces New PD-L1 Antibody for Immuno-Oncology Research b3cnewswire
July 24, 2018
Abcam, a global innovator in life science reagents and tools today announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Abcam, Merck Launch Anti-PD-L1 Antibody Clone contractpharma
July 03, 2018
Abcam announced the commercial launch of the new anti-PD-L1 antibody clone MKP1A07310 (clone 73-10) developed in collaboration with Merck KGaA, Darmstadt, Germany.
Abcam and Shuwen Biotech Sign Strategic MoU to Establish Global Alliance for Companion Diagnostic (CDx) Kit Development b3cnewswire
May 23, 2018
Abcam, a global leader in the supply of life science research tools, today signed a Memorandum of Understanding (MoU) with Shuwen Biotech, a leading player in the development and commercialization of companion diagnostics (CDx).
Abcam ends pursuit of £270M Horizon Discovery buyout fiercebiotech
May 10, 2018
Even without taking over Horizon, Abcam could still seek to satisfy its “strong interest in pursuing strategic expansion in the gene editing market” through some other means. (Abcam)

Previous page 1 2 Next page